Compare ORN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORN | AUTL |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.4M | 431.2M |
| IPO Year | 2007 | 2025 |
| Metric | ORN | AUTL |
|---|---|---|
| Price | $10.64 | $1.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $16.25 | $8.50 |
| AVG Volume (30 Days) | 426.4K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | 28.33 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $852,260,000.00 | $10,120,000.00 |
| Revenue This Year | $7.08 | $669.62 |
| Revenue Next Year | $9.52 | $79.78 |
| P/E Ratio | $180.83 | ★ N/A |
| Revenue Growth | 7.01 | ★ 496.00 |
| 52 Week Low | $4.64 | $1.11 |
| 52 Week High | $15.00 | $2.70 |
| Indicator | ORN | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 30.16 | 44.00 |
| Support Level | $9.90 | $1.46 |
| Resistance Level | $11.70 | $1.52 |
| Average True Range (ATR) | 0.94 | 0.11 |
| MACD | -0.39 | -0.02 |
| Stochastic Oscillator | 6.78 | 3.23 |
Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar and mesh across the light commercial, structural and other associated business areas.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.